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ABSTRACT 
FGFR4 and β-Klotho in Metastatic Prostate Cancer 
by 
Derek LaMar Shenefelt 
Fibroblast growth factors and fibroblast growth factor receptors have been 
associated with the aggressiveness and progression of Prostate Cancer (PCa). Also, β-
Klotho is a known co-receptor with FGFR4 for FGF19 in the liver however, the role of 
this co-receptor pair remains unclear in the setting of PCa.  
I demonstrated that FGFR4 and KLB mRNA and protein are highly expressed in 
PCa cells when compared to bone marrow stromal cells, a common site of metastasis. I 
also provide support for the association of FGFR4 and KLB in PCa, suggesting a 
functional co-receptor pair capable of altering cellular signaling. FGFR4-KLb may also 
provide some level of protection to PCa cells from chemotherapeutics.  
This analysis of FGFR4 and KLB expression and signaling in PCa has provided 
novel insights into phenotypic alterations during PCa progression while also providing 
new avenues of study to further explore the role and importance of this exciting co-
receptor complex.  
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Chapter 1 
Introduction 
1.1. Metastatic prostate cancer 
Prostate Cancer (PCa) is the most commonly diagnosed and second leading cause of cancer 
deaths in American men [9]. PCa originates as an epithelial disease, yet in metastatic disease, 
these cells primarily “home” to mesenchymal tissues such as bone [12, 31]. The bone 
microenvironment is quite hostile to epithelial cells and inherently prevents survival of epithelial 
cancer cells. However, PCa metastatic cells have been shown to adopt osteoblast characteristics 
by upregulating osteopontin (OPN), osteocalcin (OC), and bone morphogenic proteins (BMPs) 
in order to increase survival in the hostile bone microenvironment [3, 12], a process that has been 
termed “osteomimicry” [12]. Many of the phenotypic adaptations that enable PCa cells to 
survive in hostile tissues can be driven through mechanisms such as osteomimicry as well as 
epithelial-mesenchymal transition (EMT). The process of EMT is thought to be a major 
mechanism that allows metastasis to leave the primary tumor and thrive in distal tissues like 
bone, yet many of the molecular mechanisms of this process remain unclear [3,12, 31]. EMT is 
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Figure 1.1. PCa progression and cell line model. The LNCaP progression model includes 
cell lines at various stages of human PCa progression. C4-2B cells were used in this study to 
investigate the role of FGFRs in osteoblastic bony metastasis.(Modified from Farach-Carson). 
 
initiated upon the loss of E-cadherin and other epithelial adhesion and extracellular matrix 
(ECM) proteins, allowing PCa cells to move from their tissue of origin. In order to survive in 
distal tissues, PCa cells are thought to adopt a mesenchymal phenotype by upregulating 
mesenchymal association proteins such as N-cadherin [31]. In Figure 1.1, PCa progression is 
depicted along with the corresponding cells of the LNCaP progression model of human PCa that 
were studied in this project. During each stage of PCa progression, cancer cells become more 
phenotypically mesenchymal and osteoblastic, thus increasing the potential for tumor formation 
and metastasis of these cells. Additionally, during EMT metastatic PCa cells often alter growth 
factor signaling to ‘mirror’ that of bone cells and these alterations maximize survivability and 
proliferation in the bone microenvironment [7, 12]. However, the complete picture of PCa 
adaptations of growth factor expression and signaling in the bone microenvironment remain 
unclear. A more complete understanding of the phenotypic alterations of PCa cells will help 
identify select pathways upon which cancer cells rely to survive in otherwise hostile 
environments and potentially direct effective and novel therapies.  
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1.1.1. Fibroblast growth factors and fibroblast growth factor receptors in 
prostate cancer 
In clinical disease, overexpression of FGFs and FGFRs has been associated with the initiation, 
progression, and aggressiveness of PCa [24, 30]. The FGFR family is comprised of four distinct 
receptors, FGFR-1 to FGFR-4, sharing between 55% and 72amin acid homology [28]. FGFRs 
are single-pass transmembrane proteins with three extracellular Ig-like domains (IgI-III) and 
stretches of acidic residues interspersing each of these domains [1]. Ig-like domains, particularly 
IgIII, are the sites to which FGFs bind and subsequently activate FGFR signaling. To provide 
ligand-binding diversity, FGFRs 1-3 undergo alternate splicing of the IgIII domain where FGFs 
primarily bind [1, 28]. Interestingly, FGFR4 is only found as one isoform and does not undergo 
alternate splicing in the IgIII domain and is also shown to be the FGFR most closely associated 
with PCa progression and aggressiveness [5, 23, 24, 28, 30].  Previously published work from 
the Farach-Carson laboratory has shown FGFR4 mRNA expression in C4-2B PCa cells, but little 
to none in HS27a bone marrow stromal cells [23]. FGFRs also contain a positively charged 
heparin/heparan sulfate binding domain that is part of the IgII domain and is required for binding 
canonical FGFs and activation of FGFR signaling [5, 32]. In the most-recently proposed 
oligomerization model of HSPG-mediated FGFR signaling, two FGFRs and two FGFs dimerize 
and are stabilized further upon HSPG binding, forming a ternary complex (Figure 1.2) [28, 32]. 
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Figure 1.2 (A) Schematic of FGFR structure. FGFRs are comprised of 3 Ig-
like domains, a transmembrane domain and an intracellular tyrosine kinase 
domain. (B) Schematic of FGFR-FGF-HSPG binding complex. Activated 
complex activates AKT and MAPK cascades. Figure adapted from  
Haugsten, E. et.al. Mol Cancer Res 2010. 
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1.1.2.  FGFR4 in prostate cancer 
Each FGFR is activated by a subset of distinct FGFs, and FGFR4 is primarily activated 
by FGF1, FGF8, FGF9, and exclusively by the FGF19 subfamily [1, 16]. Once the FGF-
FGFR-HSPG complex is formed, the cytosolic RTK domain, containing up to seven 
tyrosine residues, transphosphorylates and subsequently activates various signaling 
cascades. Phosphorylated FGFRs activate the Ras/MAPK and the PI3K/AKT pathways, 
both of which have been strongly associated with mitogenesis and other cell survival 
pathways in cancer [16, 21]. However, FGFR4 has been shown to activate the 
Ras/MAPK, PLCγ, and ATK pathways to a lesser extent than the other FGFRs even 
though FGFR4 binds mitogenic FGFs [29, 30, 35]. In their study, Vainikkak et al. 
determined that compared to FGFR1, FGFR4 only weakly induced MAPK 
phosphorylation, tyrosyl phosphorylation of PLCγ, and was not found to bind GRB2 even 
though an increase in mitogenesis was seen [33]. Wang et al. also found that compared to 
FGFR1, FGFR4 induced a lower degree of ERK phosphorylation and lower RNA 
expression of two potent transcription factors fos and tis11 [35]. These data suggest that 
activated FGFR4 does not induce mitogenic signaling pathways as strongly as FGFR1-3 
and may be activating other nonmitogenic pathways that also provide increased survival 
in the hostile bone environment. FGFR4 has also been implicated in the regulation of 
cellular metabolism. Interestingly, activation of FGFR4 by FGF19 reduced expression of 
a potent metabolic regulator acetyl-CoA carboxylase2 (ACC2), suggesting oxidation of 
fatty acids and increased cellular metabolism [6]. By exploiting FGFR4 and FGF19 
signaling that increase cellular metabolism, PCa cells may gain a competitive advantage 
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over the surrounding microenvironment, thus increasing tumor growth and survival in the 
surrounding bone marrow microenvironment. 
1.1.3.  FGFR4 and β-Klotho in prostate cancer 
As discussed previously, FGF 1, 8, and 9 are activators of FGFR4 and act as potent 
mitogens that have been implicated in PCa progression. FGFR4 is also the exclusive 
receptor for FGF19s [1, 16, 27]. FGF19s are potent regulators of metabolism and vitamin 
D regulation of minerals in bone and unlike the canonical FGFs, the FGF19 subfamily 
has weak binding affinity for HSPGs allowing FGF19s to evade much of the extracellular 
matrix and act as endocrine signaling factors [1, 21]. However, the reduced 
heparin/heparan sulfate-binding affinity also reduces the ability of FGF19s to bind 
FGFRs. In order for FGF19 and FGFR4 interaction, the transmembrane cofactor β-
Klotho (KLB) is required [15]. The Klotho gene family, composed of α-Klotho and KLB 
are transmembrane glycoproteins whose extracellular domain consists of beta-
glycosidase-like repeats and share approximately 41% amino acid homology [14, 21]. 
KLB is primarily expressed in the liver and to lesser extent in the prostate, pancreas, 
kidneys and adipose tissues and is known to enhance FGF19 association with FGFR4 in 
humans to regulate lipid and glucose metabolism. Interestingly, the FGFR4-KLB receptor 
complex has been shown to “induce apoptosis and inhibit tumor cell proliferation” in the 
liver [21]. Together, these studies suggest that FGFR4 and KLB are involved in 
regulating both mitogenic and metabolic pathways to regulate cancer cell behavior; 
however, few studies have investigated the signaling pathways of FGFR4 and KLB in the 
setting of PCa bone metastasis. The experiments that I undertook were designed to 
elucidate the expression levels of FGFR4 and KLB in both PCa and bone marrow stromal 
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cells (BMSCs) as well as to determine the role of these co-receptors in mitogenic, cell 
survival and/or metabolic signaling thus provide attractive signaling targets for future 
cancer treatments. If FGFR4 and KLB are more highly expressed in PCa, FGFR4 and 
KLB may also provide enhanced mitogenic, survival and/or metabolic signaling that 
enables PCa cell survival and growth in an otherwise hostile bone microenvironment. An 
understanding of FGFR4 and KLB expression and signaling will not only increase our 
knowledge of tumor biology, but FGFR4 and KLB may be an attractive coreceptor 
complex for targeting anti-cancer therapies.
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Chapter 2 
Materials and Methods 
2.1. Cell Culture 
LNCaP, C4, C4-2 and C4-2B cells (a gift of Dr. Leland Chung) were grown in T-medium 
(Gibco BRL/Life Technologies, Carlsbad, CA) and supplemented with 10% (v/v) heat-
inactivated fetal bovine (FBS), 1%(v/v) penicillin/streptomycin and 1%(v/v) L- 
glutamine. Growth media was changed every 48 hours and cells were passaged at 80% 
confluency with 0.25% (w/v) trypsin containing 1X ethylenediamine tetraacetic acid 
(EDTA). HS27a and HepG2 (ATCC, Manassas, VA) cells were grown in Low Glucose 
Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented 
with 10% (v/v) FBS and 1% Penicillin-Streptomycin (PS). Medium was changed every 
48 hours and passaged at 80% confluency with 0.25% (w/v)trypsin containing 1X EDTA. 
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2.1.1. FGF19 Iand FGF1 treatments 
C4-2B cells were grown in 6-well plates and maintained as described above. At 50% 
confluency (judged by microscopic inspection), cells were placed into fresh media for 48 
h prior to all FGF treatments. Cells were then incubated with 0.1% (w/v) BSA vehicle 
control, 200 ng/mL recombinant human FGF19 (R&D Systems, Minneapolis, MN) or 
200 ng/mL of recombinant human FGF1 (R&D Systems, Minneapolis, MN) for 6 h or 24 
h in a humidified atmosphere of air:CO2 (95:5; v/v). Protein then was extracted for 
western blot analysis. Protein was extracted from a 6-well plate using RIPA lysis buffer, 
1%  (v/v) phenylmethylsulfonyl fluoride (PMSF), 1% protease inhibitor cocktail 
including inhibitors of serine proteases, amino-peptidases, cysteine proteases, and 
metalloproteases and 1%  (v/v) sodium orthovanadate (Santa Cruz Biotechnology, Santa 
Cruz, CA). Protein concentration was determined using a BCA assay (Thermo Fisher 
Scientific). Proteins were separated using NUPAGE sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (Invitrogen) for 55 minutes at 200 V. 
Proteins were transferred to a nitrocellulose membrane at 4°C for 2 h at 60 V. The 
membrane was blocked in a solution of 3% (w/v) BSA in TBST for 2 h at 25°C while 
shaking. The membranes then were incubated with either 5μg/mL FGFR4 antibody(sc-
136988, Santa Cruz Biotechnology) and 5μg/mL, β-Klotho (LS-B3568, LifeSpan 
Biosciences, Seattle, WA) at 5μg/mL, p-ERK antibody (05-797R, EMD Millipore)at a 
1:2,000 dilution,  p-S6 antibody (4858, Cell Signaling Technology, Inc) at a 1:2,000 
dilution, or β-actin antibody (Ab8226, Abcam) at a 1:10,000 dilution and incubated 
overnight at 4°C while shaking. The blots were then washed three times with Tris-
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buffered saline with tween 20 (TBST) for 5 minutes each with gentle rotary agitation. 
Blots then were incubated with anti-rabbit or anti-mouse horseradish peroxidase (HRP)-
conjugated secondary antibodies at 1 1:500 dilution (Sigma-Aldrich, St. Louis, MO). 
Again, the blot was washed three times with TBST and finally incubated with Pierce 
ECL Western Blotting Substrate (Invitrogen) for 10 minutes at 25°C. Prior to being re-
probed with other primary antibodies, blots were incubated with Restore Western Blot 
Stripping Buffer (Pierce) according to the manufacturer’s protocol.  
2.1.2. Camptothecin treatments and live/dead assay 
C4-2B cells were grown in 6-well plates and maintained as described above. At 50% 
confluency, cells were placed in fresh media for 48 h prior to all FGF treatments. Cells 
were then incubated with 0.1% BSA vehicle control, 200ng/mL FGF19 or 200ng/mL 
FGF1 for 6 h at 37°C in a humidified atmosphere of air:CO2 (95:5, v/v). Media was 
removed and cells were then incubated with 1 μL of vehicle control DMSO or 0.574μM 
camptothecin(MP Biomedicals, Solon, OH) for 24 h. following FGF and drug treatments, 
Live/dead staining was carried out as follows:  Growth medium was removed and 
Calcein AM and Ethidium homodimer nucleic acid stain (Invitrogen) were incubated 
with cells at 1:1000 (v/v) in Dulbecco’s Phosphate-Buffered Saline (DPBS). 1mL of 
live/dead mixture was added for 15 min then cell fluorescence was visualized a Zeiss 
Axioplan 2 microscope (Carl Zeiss Microscopy, Thornwood, NY, USA). 
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2.2. RNA isolation and qRT-PCR 
Total RNA was extracted from cells using TRIzol reagent (Invitrogen) following 
manufacturer’s protocol. cDNA was synthesized with a qScript cDNA SuperMix kit 
(Quanta Biosciences, Gaithersburg, MD) according to manufacturer’s protocol. Equal 
volumes of cDNA were used as template for qRT-PCR using iQ SYBR Green Supermix 
(Bio-Rad) according to manufacturer’s protocol (See table 2 for all primer sequences 
used).   
Target Primer Sequence 
β-Klotho FWD 5’-ACGGCGACATGGACATTTAC-3’ 
β-Klotho REV 5’-CATCCTCCAGAGCCTGGTC-3’ 
FGFR4 FWD 5’-AGCCAGGTGAGGAGGAGCCA-3’ 
FGFR4 REV 5’-GGCCCAGGCACACTCAGCAG-3’ 
ACC2 FWD 5’-TTATCTGACCACAGGTGAAGCTGAGA-3’ 
ACC2 REV 5’-GCTCCGGAAGTTTAGGGTTTTCTAAAG-3’ 
 Table 2.1-Sequences of oligonucleotides used in this study 
2.3. Western blot analysis 
C4-2B cells were grown as described above. Protein was extracted from a 6-well plate 
using RIPA lysis buffer, 1%  (v/v) phenylmethylsulfonyl fluoride (PMSF), 1% (v/v) 
protease inhibitor cocktail including inhibitors of serine proteases, amino-peptidases, 
cysteine proteases, and metalloproteases, and 1% (w/v) sodium orthovanadate (Santa 
Cruz Biotechnology, Santa Cruz, CA). Protein concentration was determined using a 
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BCA assay (Thermo Fisher Scientific). Proteins were separated using NUPAGE sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Invitrogen) for 55 
minutes at 200 V. Proteins were transferred to a nitrocellulose membrane at 4°C for 2 h at 
60 V. The membrane was blocked in a solution of 3% (w/v) BSA in TBST for 2 h at 
25°C with gentle rotary agitation. The membranes then were incubated with either 
5μg/mL FGFR4 antibody(sc-136988, Santa Cruz Biotechnology) and 5μg/mL, β-Klotho 
antibody (LS-B3568, LifeSpan Biosciences, Seattle, WA) at 5μg/mL, p-ERK antibody 
(05-797R, EMD Millipore)at a 1:2,000 dilution,  p-S6 antibody ( 4858, Cell Signaling 
Technology, Inc) at a 1:2,000 dilution, or β-actin antibody (Ab8226, Abcam) at a 
1:10,000 dilution and incubated overnight at 4°C with gentle rotary agitation. The blots 
were then washed three times with TBST for 5 minutes each with gentle rotary agitation. 
Blots then were incubated with anti-rabbit or anti-mouse horseradish peroxidase (HRP)-
conjugated secondary antibodies (Sigma-Aldrich, St. Louis, MO). Again, the blot was 
washed three times with TBST and incubated with Pierce ECL Western Blotting 
Substrate (Invitrogen). Prior to being re-probed with other primary antibodies, blots were 
incubated with Restore Western Blot Stripping Buffer (Pierce) according to the 
manufacturer’s protocol. 
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 Target Host Company Catalog # 
FGFR4 Mouse monoclonal Santa Cruz Biotechnology sc-136988 
β-Klotho Rabbit polyclonal LifeSpan BioSciences LS-B3568 
p-ERK Rabbit monoclonal EMD Millipore 05-797R 
p-S6 Rabbit monoclonal Cell Signaling Technology 4858 
β-actin Mouse monoclonal Abcam Ab8226 
Table 2.2-- List of antibodies used in this study 
 
2.4. Immunofluorescence 
Cells were grown on square coverslips (VWR International, Randor, PA) in 6-well plates 
as described above. Medium was removed and cells were fixed in 4% (w/v) 
paraformaldehyde (PFA) (MP Biochemicals, Solon, OH) in ddH2O. PFA was removed 
and cells were washed in phosphate buffered saline (PBS). Cells were then blocked in 1% 
(w/v) BSA in PBS for 30 minutes at 25°C in a humidified chamber. Cells were 
subsequently incubated with 5μg/mL mouse anti-FGFR4 (Abcam, Cambridge, MA) and 
5μg/mL rabbit anti-β-Klotho (LifeSpan Biosciences, Seattle, WA) at 4°C overnight. Cells 
were washed in PBS followed by 1:500 solutions of anti-mouse AlexaFluor 488 and anti-
rabbit AlexaFluor 568 (Invitrogen) for one hour at 25°C, washed in PBS, incubated for 1 
minute in a 1μg/mL 4',6-diamidino-2-phenylindole (DAPI) solution (EMB Millipore) and 
washed in PBS before mounting the coverslips on slides. Slides were imaged with a Zeiss 
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Axioplan 2 microscope at 40X magnification (Carl Zeiss Microscopy, Thornwood, NY, 
USA). 
2.5. in situ Proximity Ligation Assay 
C4-2B and HS27a cells were grown on coverslips in 6-well plates as described above. 
Medium was removed and cells were fixed in 4% (w/v) paraformaldehyde (PFA) (MP 
Biochemicals, Solon, OH) in ddH2O. PFA was removed and cells were washed in 
phosphate buffered saline (PBS). Cells were then blocked in 1% (w/v) BSA in PBS for 
30 minutes at 25°C. Cells were subsequently incubated with 5μg/mL mouse anti-FGFR4 
(Abcam, Cambridge, MA) and 7μg/mL rabbit anti-β-Klotho (LifeSpan Biosciences, 
Seattle, WA) at 4°C overnight. As a control for non-specific PLA signal, mouse anti-
Neuron-Specific Enolase (NSE) was used in place of anti-FGFR4 antibody.  Following 
washes with PBS, the in situ Proximity Ligation Assay was performed according to the 
manufacturer’s protocol using Duolink II PLA probe anti-Mouse PLUS and Duolink II 
PLA probe anti-Mouse MINUS and detected with Duolink II Detection Reagents Red 
(OLink Bioscience, Uppsala, Sweden). Coverslips were mounted with DAPI mounting 
media (OLink) on microscope slides and images were obtained with a Zeiss Axioplan 2 
microscope at 40X magnification (Carl Zeiss Microscopy, Thornwood, NY, USA). All 
FGFR4-KLB PLA images and minus KLB primary antibody control samples were color-
enhanced in parallel to reduce background. The mean PLA signal from the NSE-KLB 
control experiment was subtracted from the mean FGFR4-KLB PLA for final statistical 
analysis. 
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2.6. β-Klotho knockdown with siRNA 
C4-2B cells were plated and maintained in 12-well plates as described above. At 60% 
confluency, media was removed and 40nM KLB siRNA (Origene, Rockville, MD) was 
added in serum-free Dulbecco's Modified Eagle Medium (Invitrogen) for 24 h. siRNA 
containing media was removed and the cells were subsequently treated with 200ng/mL 
FGF19 or FGF1 in appropriate growth media for 24 h. Protein was collected and western 
blotting analyses were conducted as described above. 
2.7. Statistical analysis 
To determine significance of FGFR4 expression levels between PCa and BMSCs, a One-
way ANOVA test and a  secondary Tukey test for multiple comparisons using GraphPad 
In-stat software. For PLA analysis, a Welch’s corrected t test was used using GraphPad 
In-stat software.  
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Chapter 3 
FGFR4 and β-Klotho expression and co-
localization during prostate cancer 
progression 
3.1. Characterization of FGFR4 and β-Klotho expression in the 
LNCaP progression model of prostate cancer 
3.1.1. Quantitative RT-PCR of FGFR4 
Previous published studies from our laboratory have shown that FGFR4 mRNA is 
expressed in C4-2B, but little or none is detectible in HS27a bone marrow stromal cells 
[23]. To quantitatively compare mRNA expression of FGFR4 between these PCa cells 
and bone stromal cells, I conducted qRT-PCR experiments in LNCaP, C4, C4-2, C4-2B 
and HS27a cells. FGFR4 primers were selected based on sequence specificity by NCBI 
Blast and designed to span introns in order to avoid genomic DNA amplification. For 
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each cell type, samples were analyzed in biological triplicate and the mean comparative 
threshold (CT) values + standard deviation (SD) was normalized to β-actin. In Figure 3.1, 
C4-2 and C4-2B cells expressed the highest levels of FGFR4. when compared to HS27a 
cells. C4, and HS27a cells express approximately 4.0 and 2.5 fold less FGFR4 
respectively when compared to C4-2B cells.  These data are consistent with previous 
literature suggesting higher FGFR4 expression is associated with both agressivness and 
the metastatic potential of the PCa cells.   
*** 
*** 
** 
actin
*** 
* 
***P value<0.001 
  **P value<0.01 
    *P value<0.05 
2Figure 3.1. FGFR4 mRNA expression in PCa and 
BMSCs. All PCa cell lines have significantly more 
FGFR4 mRNA than HS27a cells. Relative FGFR4 mRNA 
expression in LNCaP, C4, C4-2 and C4-2B cells are 2, 6, 
9 and 8-fold higher than HS27a cells, respectively.  
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Figure 3.2.  RT-PCR analysis of 
KLB mRNA. KLB mRNA is highly 
expressed in C4-2B cells but not 
HS27a cells   
 
 
3.1.2. qRT-PCR of β-Klotho 
To determine KLB mRNA expression in PCa and bone stromal cells, I conducted similar 
RT-PCR experiments designed to determine 
FGFR4 mRNA expression in C4-2B and 
HS27a cells [23]. In Figure 3.2., a strong 
signal for KLB cDNA of approximately 
281bp was found to be present in C4-2B cells, 
but not HS27a cells.  
To more fully determine the extent of KLB expression in PCa cells, I conducted qRT-
PCR experiments in the LNCaP series and HS27a cells. Primers were selected from a 
literature article exploring KLB expression in colonic tissues and similarly to the 
FGFR4 qRT-PCR experiments discussed above, each cell type was analyzed in 
biological triplicate with the mean comparative threshold (CT) values +SD was 
normalized to β-actin [47]. In Figure 3.3, KLB mRNA is expressed approximately 
15-fold higher in LNCaP, 25-fold higher in C4, 26-fold higher in C4-2 and 33-fold 
higher in C4-2B when compared to HS27a cells (Figure 3.3).  These data suggest that 
KLB is highly expressed in PCa cells when compared to BMSCs, similar to FGFR4 
and these two proteins have the potential to form a functional co-receptor complex for 
enhanced PCa cell signaling in the bone marrow microenvironment.  
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***P value<0.001 
  **P value<0.01 
    *P value<0.05 
Figure 3.3. KLB mRNA expression in PCa and BMSCs. All PCa cell lines express 
significantly more KLB mRNA than HS27a cells. Relative KLB mRNA expression in  
LNCaP, C4, C4-2 and C4-2B cells are 16, 25, 26 and 22-fold higher than HS27a cells, 
respectively.  
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3.1.3.  Western blot analysis of FGFR4 and β-Klotho in PCa and bone marrow 
stromal cells. 
qRT-PCR demonstrates differences in mRNA levels of FGFR4 and KLB among the 
cell lines examined; however, it is also important to assay protein expression, 
especially when investigating the role of two cell surface receptors and their potential 
role in various cellular signaling pathways. To this end, western blotting was chosen 
to be the best assay for both FGFR4 (90-125 kDa) and KLB (120kDa). Protein was 
isolated from the LNCaP progression model, HS27a bone marrow stromal cells and 
as a positive control, HepG2 hepatocarcinoma cells. FGFR4 and KLB have been 
studied extensively in HepG2 cells and these cells provide an excellent positive 
control cell for the following experiments.  Mean intensity values for FGFR4 and β-
actin band intensity were determined and used to calculate the FGFR4:β-actin ratio 
for analysis. In Figure 3.4,  LNCaP, C4, C4-2, and C4-2B cells were each found to 
express approximately 4-fold higher FGFR4 protein when compared to HS27a cells, 
each with a p-value of <0.001 (Figure 3.4). These data provide further evidence that 
FGFR4 is more highly expressed in PCa cells and may play an important role in 
cellular signaling. 
Similarly, PCa cells expressed approximately 4-fold higher KLB protein than 
compared to Hs27a cells, with a p-value of <0.001 (Figure 3.5). Taken together, these 
data suggest that FGFR4 and KLB are highly expressed in PCa cells when compared 
to BMSCs. Furthermore, the 4-fold higher expression of both FGFR4 and KLB in 
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PCa cells when compared to HS27a cells indicates the potential for formation of co-
receptor pairs that would be required for potential FGF19-mediated metabolic 
signaling.  
 
  
*** 
***P value <0.001 
ng/mLF
GFR4 
 
Figure 3.4. Western blot analysis of FGFR4 protein expression in 
PCa, BMSC and HepG2 cells. PCa cell lines all significantly more 
FGFR4 protein than compared to Hs27a cells. HepG2 cells were used 
as a positive control.  
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*** 
***P value <0.001 
KLB 
 
ERKFigure 3.5. Western blot analysis of KLB protein expression 
in PCa, BMSC and HepG2 cells. PCa cell lines all express 
significantly more KLB protein than compared to Hs27a cells. 
HepG2 cells were used as a positive control.  
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3.1.4. Immunofluorescence of FGFR4 and β-Klotho 
To more fully identify differences of FGFR4 and KLB expression between PCa and bone 
stromal cells, I used  immunofluorescence to stain C4, C4-2, C4-2B, and HS27a cells 
with mouse monoclonal antibodies to human FGFR4 and rabbit polyclonal antibodies to 
KLB, both of which were raised against an extracellular epitope of the respective 
receptor. HS27a cells were chosen for these experiments because they are structural 
stromal cells that do not secrete cytotoxic factors that would prohibit co-culture with PCa 
cells. The primary antibodies were detected by incubation with anti-mouse AlexaFlour 
488 and anti-rabbit AlexaFlour 568. In Figure 3.6, C4-2B cells express strong, 
homogeneous signals for FGFR and KLB, both of which encompass the cytoplasm of 
each cell. C4-2 and C4 cells have more modest staining for both FGFR4 and KLB and 
when comparing the merged images, C4-2 and C4 cells have much more heterogeneous 
staining patterns of FGFR4 and KLB. HS27a bone stromal cells have little detectable 
FGFR4 and KLB when compared to C4-2B (Figure 3.6). As discussed previously, tumor 
cells are often surrounded by stromal cells and interactions between cancer cells and the 
surrounding microenvironment can drive various phenotypic alterations, such as FGF 
signaling. Similarly, bone metastatic PCa cells are surrounded by BMSC, and in order to 
visualize FGFR4 and KLB expression in a similar environment, I co-cultured C4-2B cells 
with HS27a BMSCs. In Figure 3.6, C4-2B cells expressed higher FGFR4 and KLB when 
compared to HS27a cells (Figure 3.6). Taken together, these data suggest that FGFR4 and 
KLB are more highly expressed and similarly distributed in PCa cells when compared to 
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bone stromal cells. Also, the expression of FGFR4 and KLB seemed to track the LNCaP 
progression model: higher levels of expression as the cell phenotype approaches a higher 
metastatic potential. Also, similar distribution of FGFR4 and KLB expression in C4-2B 
cells suggests possible co-localization required for effective FGF19 signaling.  
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C42B 
HS27a 
C42B 
HS27a 
C42B 
HS27a 
FGFR4 KLB Merge 
C4 
Hs27a 
Co-Culture 
Figure 3.6. Immunofluorescent staining of 
FGFR4 and KLB in PCa and BMSCs. 
Imaged at 40X, HS27a cells have little 
FGFR4 (green) or KLB (red) signal. C4 and 
C4-2 cells have modest signal of both 
FGFR4 and KLB.C4-2B cells express 
strong, homogeneous signal for FGFR4 and 
KLB. In co-culture, HS27a and C4-2B cells 
were distinguished based on morphology 
the strong FGFR4 and KLB signals are 
clearly seen in C4-2B cells when compared 
to Hs27a.  
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3.2. Association of FGFR4 and β-Klotho in PCa cells 
3.2.1. In situ co-localization of FGFR4 and KLB in C4-2B and HS27a cells. 
To determine co-localization of FGFR4 and KLB in PCa cells, I used a Duolink in situ 
Proximity Ligation Assay (PLA).  This PCR amplification assay is capable of detecting 
protein interactions if the proteins of interest are within 40nm of each other. For the 
assay, I used the same mouse monoclonal antibodies to human FGFR4 and rabbit 
polyclonal antibodies to KLB that recognize extracellular epitopes of these two receptors 
discussed previously. C4-2B and HS27a cells were incubated with primary antibodies 
followed by anti-mouse and anti-rabbit secondary antibodies conjugated to unique DNA 
strands and linker oligonucleotides that allow the formation of a circularized DNA 
molecule. After incubation with a DNA ligase followed by DNA polymerase, that 
initiates rolling circle amplification, a concatamer of DNA is formed. Fluorescently-
labeled complementary DNA probes hybridize to the concatamer and a high 
concentration of fluorescence can be detected for a FGFR4:KLB protein complex.  
For this assay, three controls were analyzed in parallel to validate the specificity of 
various aspects of the assay: First, a technical positive control slide provided in the kit 
was used to determine the functionality of all PLA kit components reagents. A “no 
primary control” was run for each cell type by omitting either FGFR4 or KLB primary 
antibodies. Thirdly, a background control was used to both validate the specificity for 
FGFR4-KLB PLA signals by incubating the cells of interest with primary antibodies 
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targeting two proteins that are not expected to colocalize. FGFR4 and Neuron Specific 
Enolase (NSE) were used in this control and the resulting FGFR4-NSE PLA signal was 
subtracted from FGFR4-KLB PLA signals as nonspecific background signal. For image 
analysis, I followed a similar protocol as did Spears et al. by counting the number of PLA 
signals per cell after a background threshold was determined [40]. For quantification, 
FGFR4-NSE control PLA signals from each cell type were subtracted from the FGFR4-
KLB PLA signals per cell and for statistical analysis, a Welch’s corrected t test was used. 
As seen in Figure 3.7, approximately 5.6 FGFR4:KLB signals per cell were seen in C4-
2B cells compared to 1.2 PLA signals  per HS27a cell with a P values < 0.001(Figure 
3.7).  These data strongly suggest that FGFR4 and KLB form a complex in PCa cells and 
not in BMSCs.  
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ERKFigure 3.7. in situ PLA of FGFR4 and 
KLB in C4-2B and HS27a cells. A: 
Representative image of C4-2B cells. PLA 
signal (Red); DAPI (Blue) B: Representative 
image HS27a cells. PLA signal (Red); DAPI 
(Blue) C: C4-2B cells express approximately 
5.6 particles per cell compared to 1.2 
particles per cell in HS27a. P value <0.0001 
*** 
***P value <0.0001 
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Chapter 4 
Characterization of FGFR4 and β-Klotho 
signaling in PCa 
4.1. FGF-mediated mitogenic, metabolic and survival signaling in 
PCa. 
As discussed above, FGFRs are activated by distinct subsets of FGFs.  Interestingly, 
FGF1 has been shown to activate all four FGFRs and although FGF1 is a universal 
activator, it does not elicit equal levels of activation across the FGFR family. FGF1 
was shown to induce higher p-ERK1/2 phosphorylation in FGFR1 expressing cells 
than FGFR4 expressing cells [33, 35]. Conversely, FGF19 signaling in the setting of 
PCa bone metastasis has yet to be investigated. The vast majority of FGF19-FGFR4 
studies have been performed in liver tissues, as FGF19 is primarily secreted into the 
ileum where it can be absorbed and pass into the blood stream. Locally, FGF19 elicits 
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strong metabolic changes in subcompartments of the liver [14, 42] and has the 
potential to initiate signaling in distal tissues that express FGFR4 and KLB.   
   
4.1.1. ERK1/2 phosphorylation as a result of FGF1 but not FGF19. 
To determine if the FGFR4-KLB complex activates the ERK/MAPK mitogenic 
pathway, I conducted a dose-response of C4-2B cells to FGF19. FGF19 was present 
in control patient serum at 205.3 + 25.97 pg/mL [49]. Coordinately, PCa tumor cells 
may see similar concentrations of FGF19 and this was used as the lowest FGF19 
treatment concentration. Other studies have used up to 300 ng/mL FGF19 to assay 
FGFR4-KLB function and this concentration was used as the maximal dose of FGF19 
for the dose-response assay [21]. Accordingly, I treated C4-2B cells with 0, 2, 20, 50, 
200 and 300 ng/mL of FGF19 followed by assaying ERK phosphorylation by western 
blotting. The same concentrations of FGF1 were used to compare ERK 
phosphorylation. FGF19 at 200ng/mL elicited maximal phosphorylation in FGF1 
treated C4-2B cells compared to vehicle controls (Figure 4.1 (A)). Conversely, 
FGF19 did not elicit ERK phosphorylation at any concentration. To verify that the 
FGF19 was active, I treated HepG2 cells with 200 ng/mL FGF19 and assayed ERK 
phosphorylation (Figure 4.1 (B)). These data suggest that FGF19 does not activate the 
ERK/MAPK cascade and subsequent cell mitogenesis in C4-2B cells.   
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4.1.2. ACC2 expression in PCa bone marrow stromal cells 
FGFR4-KLB signaling may be responsible for enhancing PCa metabolic signaling 
pathways for cellular growth and success in the bone marrow microenvironment, such 
as increase fatty acid oxidation and glucose uptake and metabolism [52]. To explore 
the role of potential FGFR4-KLB mediated metabolic signaling, I assayed acetyl 
coenzyme A carboxylase 2 (ACC2) mRNA expression in PCa and BMSCs. ACC2 is 
the rate limiting enzyme responsible for fatty acid biosynthesis. Specifically, ACC2 
catalyzes the carboxylation of acetyl-CoA to malonyl-CoA which in turn inhibits the 
rate-limiting step in fatty acid uptake and oxidation by the mitochondria. In cells with 
high lipid oxidation rates, such as liver cells, reduced ACC2 expression would result 
in increased fatty acid uptake and oxidation, indicating an enhancement of cellular 
metabolism by way of fatty acid catalysis [6]. FGF19 treated mice have been shown 
0ng/mL 0ng/mL200 ng/mL 200 
FGF1 FGF19 
p-
β-actin 
Figure 4.1.  ERK1/2 phosphorylation in FGF1 and FGF19-treated C4-2B cells and 
FGF19-treated HepG2cells.  FGF1-treated C4-2B cells show ERK phosphorylation at 
42 and 44 kDa, respectively. FGF19 does not induce ERKphosphorylation  in C4-2B cells 
but strongly activates ERK phosphorylation in HepG2 cells.  
β-
p-
FGF19-treated 
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Figure 4.2. Relative ACC2 mRNA 
expression  is approximately 39-fold 
higher in HS27a cells when compared to 
C4-2B cells. ***P value <0.0001 
 
*** 
to have lower serum triglycerides and lower expression of ACC2 in the liver, 
suggesting higher fatty acid metabolism [6].  
To determine if PCa cells have 
enhanced cellular metabolism as a 
result of FGFR4-KLB signaling, I 
conducted a qRT-PCR of ACC2 
mRNA in C4-2B and HS27a cells. C4-
2B and HS27a cells grown under 
normal culture conditions described 
above. Upon analysis, untreated C4-2B 
cells express virtually no ACC2 mRNA 
as the qRT-PCR CT was near that of 
the corresponding “no template 
controls”. Reciprocally, HS27a cells express approximately 39-fold higher ACC2 
mRNA than C4-2B cells (Figure 4.2). These data suggest that C4-2B cells have 
the potential for high levels of fatty acid uptake and oxidation as a result of 
reduced ACC2 expression when compared to HS27a cells. Future studies should 
pursue this pathway further by investigating the fatty acid uptake differential 
between C4-2B and HS27a cells.  
4.1.3. pS6 phosphorylation in PCa cells 
To further characterize FGFR4-KLB regulation of cellular signaling, expression of 
phospho-S6 ribosomal protein (pS6) was assayed in the presence and absence of 
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FGF19 or FGF1.   pS6 is mainly responsible for regulating the translation of mRNAs 
of proteins required for the cell cycle. To do so, p70 S6 kinase activates pS6 after the 
cell is stimulated by GFs. pS6 increases the translation of critical proteins and thus 
allows the cell cycle to progress. It may be beneficial to assay components of pS6, 
such as Phospho-4E-BP1 that is involved in the regulation of mRNA translation to 
understand this important pathway of cellular growth [45, 46]. 
To assay the role of FGFR4-KLB induction of pS6, C4-2B cells were treated with 
200ng/mL FGF19 or FGF1 for 24 h. As seen in Figure 4.3., neither FGF19 nor FGF1 
elicited an increase in baseline pS6. These data suggest that FGFR4-KLB does not 
increase pS6 and may not be involved with advancement of the cell cycle above that of 
canonical FGF signaling.       
200 ng/mL 200 ng/mL 0 ng/mL 0 ng/mL 
p-S6 
β-actin 
FGF19 FGF1 
Figure 4.3. Expression of pS6 in C4-2B cells treated with FGF19 and FGF1 treatment. Neither 
FGF19 nor FGF1 treatment enhanced pS6 expression in C4-2B cells above untreated controls 
suggesting  that FGF19 nor FGF1 are regulators of the pS6 cell-cycle regulation cascade.  
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4.2. FGF1 and FGF19-mediated resistance to chemotherapeutics 
4.2.1. Camptothecin treatments 
Camptothecin [CPT] is a long established anti-cancer compound known to induce 
apoptosis in PCa cells. This drug has been used extensively in studies involving C4-2B 
cells and provides an excellent avenue to explore the role of FGFR4-KLB in mediating 
resistance to chemotherapeutics [8].   
 
To determine if FGFR4-KLB provides any resistance to chemotherapeutic-induced 
apoptosis, C4-2B cells were pretreated with FGF19 or FGF1 for 24h followed by 0.574 
μM CPT. This concentration of CPT was determined to be the optimal concentration to 
inducing a sufficient apoptotic response in C4-2B cells grown on plastic by Gurski et al. 
[8]. Live/Dead staining was done following FGF and CPT treatments, providing 
qualitative data as to the degree of apoptotic resistance. As seen in Figure 4.4., C4-2B 
cells treated with vehicle appear morphologically ‘healthy’, as seen in the first column of 
bright field (BF)images,  a majority of which have robust green fluorescent signal, 
indicating living cells and no detectible red fluorescent signal, indicating dead cells.  
Conversely, C4-2B cells treated with only CPT have a less healthy morphology, indicated 
by a rounder shape and more detached and floating cells. Although many of the CPT 
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treated cells have robust green fluorescence, far more of these cells have robust red 
staining, indicating cellular death. Additionally, the majority of the detached, floating 
masses of cells had little green fluorescence, a majority of which had high levels of red 
fluorescence (data not shown). Interestingly, cells pretreated with FGF19 and FGF1 also 
have robust green fluorescence; however, fewer dead cells are seen when compared to 
CPT only treatment. Morphologically, these cells did not appear to be as ‘healthy’ as 
vehicle treated cells as they appear more round and detached, but not to the extent seen in 
CPT only treatments, suggesting a potential FGF-mediated protection from 
chemotherapeutic-induced apoptosis.   
 
  
BF Live Dead 
Vehicle 
CPT 
FGF19 + CPT 
FGF1 + CPT 
 
Figure 4.4.Live Dead 
assay of FGF19 and 
FGF1 suggesting 
pretreatment may 
protect PCa cells from 
chemotherapeutics. Cells 
were pre-treated with 
FGF19 or FGF1 and 
visualized at 40X. Cells 
pretreated with 200ng/mL 
FGF1 or 200ng/mL 
FGF19 look healthier 
(BF) and have fewer dead 
cells when compared to 
vehicle controls (Dead).  
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4.3. β-Klotho knockdown  
To help elucidate biological significance of FGFR4 and KLB expression in PCa cells, I 
conducted siRNA experiments to reduce KLB mRNA. KLB siRNA was chosen over 
FGFR4 siRNA due to the requirement of KLB for all FGF19 mediated signaling with 
FGFR4. If FGFR4 siRNA were used, all FGFR4 signaling, both canonical and KLB-
mediated would be disrupted, rather than the KLB-FGFR4 pathway specifically. Three 
KLB siRNAs were purchased from Origene and prepared as per manufacturer’s protocol. 
After 24 h incubation with the siRNA, cells were treated with FGF19 or FGF1. 
Subsequently, protein was isolated and western blots were probed for KLB, FGFR4, pS6 
and β-actin. As seen in Figure 4.5, none of the three different KLB-targeted siRNAs were 
able to effectively knock down KLB transcripts below levels observed with scrambled 
siRNA control. The untreated control KLB band is much stronger than any of the siRNA 
treatments and this can be attributed to a loss of cells after 24 h incubation with the 
respective FGFs. These cells were in the presence of the transfection reagent for a longer 
period of time which would account for the lower overall protein expression (Figure 4.5).  
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Figure 4.5. KLB siRNA treatment of C4-2B cells. Cell were treated with 
siRNA for 24 h then incubated with 200 ng/mL FGF1 or FGF19 prior to 
protein isolation. None of the three independent siRNAs effectively knocked 
down KLB transcripts over scrambled siRNA control. pS6 still exhibits a 
strong signal and FGFR4 levels remain unchanged when compared to 
scrambled siRNA control. 
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Chapter 5 
Discussion 
5.1. General Discussion 
The rate of PCa progression between individual patients can be very difficult to predict. For 
some, it is very slow growing and can go largely unnoticed. For others, PCa can progress very 
rapidly. When PCa cells metastasize to bone, the disease is often very painful and ultimately 
lethal. The bone microenvironment is quite inhospitable to normal prostatic epithelial cells that 
retain many epithelial properties [38]. In order for metastatic PCa cells to adapt and survive in 
the hostile bone microenvironment, they must adopt bone-like phenotypes by upregulating 
osteoblastic signaling molecules. FGF signaling pathways also have been linked to initiation, 
progression and aggressiveness of PCa [16, 21]. In clinical disease, overexpression of FGFs and 
coordinate FGFRs, are considered hallmarks of metastatic cancer cell adaptation that promote 
increased cellular motility and tumor invasiveness, angiogenesis, and inhibition of apoptosis that 
 39 
 
increases cancer cell survival [51]. Cancer cells often rely upon interactions and signaling from 
surrounding stromal cells to obtain phenotypic changes that enable PCa cell survival [50].  
 
The FGFR family is comprised of four distinct receptors, FGFRs-1-4, with FGFR-4 being most 
closely-associated with PCa progression in many cancer cells.  FGFR4 is activated by the FGF1, 
FGF8, FGF9, and FGF19 subfamilies, which, upon binding HSPG-receptors such as syndecan-1 
or perlecan, bind to FGFR4, causing dimerization and transphosphorylation. Interestingly, the 
FGF19 weakly binds HSPGs, allowing FGF19 to diffuse more freely through the extracellular 
matrix and act as an endocrine signaling factor. However, the reduced heparin-binding affinity 
also reduces the ability of FGF19s to bind FGFRs. In order for FGF19 and FGFR4 to interact the 
KLB coreceptor is required.  The Klotho gene family is associated with regulating lipid and 
glucose metabolism in the liver through interactions with FGFRs. KLB is primarily expressed in 
the liver and, to lesser extent, in the prostate and kidneys. KLB expression is associated with 
inhibition of apoptosis and stimulation of angiogenesis, however, the role of KLB and its 
interplay with FGF signaling in PCa remains unclear. 
 
Because of the importance of FGF signaling in PCa progression and the unknown nature of KLB 
in PCa, this study focused on the investigation of these two important signaling molecules 
throughout disease progression. 
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5.2. FGFR4 and KLB are highly expressed in PCa cells. 
To first explore the role of FGFR4 and KLB in PCa, I assayed mRNA levels for these 
proteins in both PCa and BMSCs. As discussed above, FGFR4 has been associated 
with PCa aggressiveness and progression [30]. If PCa cells express higher levels of 
FGFR4 than surrounding BMSCs, the cancer cells can exploit an arm of FGF 
signaling that remains inaccessible to the surrounding stroma. Previous work in our 
lab found high FGFR4 mRNA expression in C4-2B cells when compared to HS27a 
cells [23]. To obtain more comparative FGFR4 mRNA expression, I conducted qRT-
PCR experiments and found high FGFR4 expression in all members of the LNCaP 
progression model of PCa when compared to HS27a cells (Figure 3.1). Interestingly, 
FGFR4 expression was highest in C4-2 and C4-2B cells, those associated with 
metastasis and specifically osteoblastic bony metastasis, respectively (Figure 3.1). 
These data suggest that PCa cells express higher levels of FGFR4 especially in later 
stages of disease. Higher expression of FGFR4 in the latter stages of disease may 
provide PCa cells that have metastasized to some of the most hostile tissues, like 
bone, to exploit signaling cascades by way of altered receptor expression profiles that 
would otherwise be unavailable to normal prostatic epithelial cells in the same 
compartment. This altered receptor expression and signaling patterns may allow these 
adaptive PCa cells to survive and thrive, leading to larger metastases as well as 
further spread of the disease.  
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Similar to the FGFR4 experiments discussed above, I first conducted KLB RT-PCR 
experiments to determine the presence of KLB transcripts in C4-2B and HS27a cells. 
Again, C4-2B cells expressed a strong signal for KLB when compared to HS27a cells 
(Figure 3.2). Again, it was important to obtain comparative KLB mRNA expression 
between PCa and BMSCs. By way of qRT-PCR, all members of the LNCaP 
expression model of PCa express high levels of KLB mRNA when compared to 
HS27a cells (Figure 3.3). Interestingly, KLB expression levels reach a maximum 
earlier that what was seen with FGFR4 transcripts. LNCaP cells express 
approximately 16-fold higher KLB mRNA than HS27a cells while C4, C4-2 and C4-
2B cells express approximately 24-fold higher KLB mRNA (Figure 3.3). These data 
not only demonstrate that KLB mRNA is expressed at higher levels in PCa cell lines, 
but also suggest that KLB expression also reach a maximum sooner in disease 
progression, when cells begin to form tumors (Figure 1.1). The early peak of KLB in 
PCa progression may be used as a marker to distinguish true PCa from other 
conditions of the prostate like benign prostatic hyperplasia that may share similar 
markers like PSA.  
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FGF signaling relies upon cell-surface protein expression to bind the appropriate 
FGFs and transmit intracellular signaling cascades. To determine FGFR4 and KLB 
protein expression in PCa and BMSC models, I conducted western blot experiments. 
Similarly to FGFR4 mRNA expression, FGFR4 protein is approximately 4-fold 
higher in C4-2B cells when compared to HS27a cells (Figure 3.4). FGFR4 protein 
expression also peaks in the LNCaP progression model when PCa cells are metastatic 
and tumorigenic as seen in FGFR4 mRNA expression. These data suggest that 
FGFR4 expression occurs early in metastasis, potentially providing enhanced FGF 
signaling and survival of PCa cells in hostile environments.  
KLB protein is also highly expressed in PCa cells when compared to BMSCs (Figure 
3.5). Consistent with KLB mRNA expression, KLB protein expression peaks early in 
PCa progression, when cells are tumorigenic and non-metastatic. These data suggest 
that KLB protein is present in PCa cells and along with FGFR4 expression, may 
provide FGF signaling avenues unavailable to the surrounding stroma thus allowing 
PCa cells to survive and thrive in an otherwise hostile microenvironment.  
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It has been shown that the formation of the FGFR-KLB complex is required for many 
signaling cascades, both mitogenic and metabolic [6]. In an initial attempt to both 
visualize FGFR4 and KLB protein expression and proximity of these two receptors, I 
immunofluorescently stained PCa and BMSCs. FGFR4 and KLB fluorescent signals 
are highest in C4-2B cells where a coordinate similar distribution of FGFR4 and KLB 
is seen (Figure 3.6). When C4-2B and HS27a cells were co-cultured, a stark 
distinction of FGFR4 and KLB can be seen in C4-2B cells, thus providing a glimpse 
into the expression levels and similar distribution of this co-receptor pair in an 
environment similar to what may be seen in bone metastatic PCa. These data provide 
further evidence that FGFR4 and KLB are highly expressed and similarly distributed 
in PCa cell lines when compared to BMSC lines. As with altered FGFR4 expression 
and the potential enhancement of FGFR4 signaling, the addition of high KLB 
expression may provide PCa cells access to signaling molecules and cascades 
normally restricted to the liver and other gastrointestinal organs. In doing so, the 
ability to utilize endocrine-like FGF19 for signaling by PCa cells in the bone would 
leave PCa cells expressing high FGFR4-KLB as the sole consumers of this FGF19 in 
the bone, providing a unique avenue for enhanced survival and another signaling 
pathway to exploit for enhanced survival in the bone microenvironemnt.   
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5.3. Association of FGFR4 and KLB 
Although the aforementioned immunofluorecence data provided insights into the 
similar distribution of FGFR4 and KLB, it was still unclear whether these co-
receptors, in fact, associate, thus providing the potential for enhanced cellular 
signaling. To determine if FGFR4 and KLB associate and form a co-receptor pair, I 
conducted an in situ Proximity Ligation Assay (PLA) targeting FGFR4 and KLB. If 
FGFR4 and KLB are within 40 nm of each other, a strong red fluorescent signal will 
result. More FGFR4-KLB complexes were found in C4-2B cells compared to HS27a 
cells (Figure3.7 A and B). These data suggest that FGFR4 and KLB are physically 
very close therefore, may form functional co-receptor pairs in PCa cells. Being that 
FGFR4 and KLB are both highly expressed and seem to be associated, forming co-
receptor pairs in PCa cells is very promising for investigating the signaling potential 
of these two molecules. With a functional coreceptor pair, PCa cells have the 
potential access to signaling molecules and cascades normally restricted to cells of 
gastrointestinal organs, providing a unique avenue for enhanced survival signaling. 
 
5.4. FGFR4-KLB-mediated mitogenic and metabolic signaling in 
PCa 
Many FGFs are able to elicit signaling responses upon binding to FGFRs, including 
FGF1 and other ‘canonical’ FGFs. FGF19 is unique in that it requires the presence of 
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FGFR4 and KLB in order to effectively alter downstream signaling pathways. To this 
end, I treated PCa cells with FGF1 and FGF19 to determine the levels of both 
mitogenic and metabolic signaling.  
 
The ERK/MAPK cascade is a well-studied mitogenic pathway and accordingly, I 
assayed ERK phosphorylation in PCa cells in response to FGF1 and FGF19 
treatments. In Figure 4.1, FGF1 was able to elicit expression of pERK1/2 suggesting 
that the FGF-FGFR signaling pathways are intact in PCa cells. However, FGF19 
treatments were unable to elicit such a response (Figure 4.1). These data suggest that 
although FGFR4 and KLB are highly expressed and associated in PCa, they do not 
regulate ERK/MAPK mitogenic pathways in PCa. These findings are not completely 
surprising in that FGFR4 has been shown to only weakly activate pERK1/2 when 
compared to FGFR1 so FGFR4-KLB may play a larger role in other signaling 
pathways both mitogenic and metabolic [33, 35].    
 
FGF19 is a well-studied metabolic regulator in liver tissue and other organs of the 
gastrointestinal tract [6]. FGF19 has been shown circulating in the blood plasma of 
control patients, suggesting that PCa patients would have circulating FGF19 that PCa 
cells would be able to utilize for signaling due to high expression of FGFR4 and 
KLB. In the same study, mice treated with FGF19 had low express levels of ACC2, 
suggesting higher fatty acid metabolism and increased cellular metabolism. 
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Accordingly, I first assayed ACC2 expression in untreated C4-2B and HS27a cells. 
C4-2B cells expressed virtually no ACC2 when compared to HS27a cells suggesting 
these cells have already enhanced their ACC2-mediated cellular metabolism. 
Although these data proved to be a dead-end for further studies involving FGF19 
treatments and KLB knockdowns, it provided important insights into the cellular 
metabolism of PCa cells. This is not to say that FGFR4-KLB does not regulate PCa 
cellular metabolism, rather, FGFR4-KLB may be involved in other arms of cellular 
energetics that the present study did not address. 
 
To further explore FGFR4-KLB signaling in PCa, I assayed the expression of a potent 
regulator of the expression of proteins critical for regulation of the cell cycle in 
response to FGFs, pS6. Upon analysis, neither the presence of FGF1 or FGF19 
altered the expression of pS6 in PCa cells above baseline no treatment controls 
(Figure 4.3). This suggests that FGFR4-KLB is not a regulator of pS6. I cannot 
completely rule out a role of FGFR4-KLB in regulation of other cell cycle regulating 
components, thus further work will be required to determine if any other aspects of 
the cell cycle are altered by this complex. 
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5.5. FGFR4-KLB may provide resistance to chemotherapeutics 
Although the data presented above is promising for the signaling potential of FGFR4-
KLB in PCa, a biologically relevant experiment is needed to illustrate the 
functionality of KLB-FGFR4. Accordingly, I treated C4-2B cells with a well-studied 
anti-cancer compound, camptothecin (CPT). In our lab, CPT has been extensively 
studied with C4-2B cells and I was able to use these as a guide for CPT doses [8]. 
Many C4-2B cells treated with CPT alone were shown to havehigh levels of 
apoptosis when compared to vehicle controls (Figure 4.4). Interestingly, cells 
pretreated with FGF1 and FGF19 exhibited fewer dead cells and live cells with a 
similar morphology to vehicle controls. These data suggest that both FGFR4-KLB 
activity and FGF1 pre-treatment may provide some degree of protection from 
chemotherapeutics. However, many of the cells in the FGF19 and FGF1 treatment 
groups were lost during various washes for removal of the CPT solution and could 
not be imaged so further data will be required to conclusively determine if FGFR4-
KLB may be providing protection against chemotherapeutic agents. Most commonly, 
cancer cells upregulate drug transporter proteins or alter DNA repair mechanisms to 
achieve chemoresistance and this may also be the case in PCa [53].  
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5.6. siRNA knockdown of KLB 
I conducted siRNA knockdown experiments targeting KLB in order to more 
completely determine the biological significance of high FGFR4-KLB expression and 
functionality in PCa cells. Unfortunately, none of the three independent KLB siRNAs 
were able to effectively knock-down KLB protein below the scrambled siRNA 
control (Figure 4.5). Not surprisingly, pS6 and FGFR4 protein expression levels 
remained unchanged in all treatment pools.  KLB siRNAs may not be providing 
adequate knockdown for a variety of reasons. A recent study by Amarzguioui et al. 
found that longer siRNAs of 25nt as opposed to the traditional 21 nt siRNAs are able 
to “serve as dicer substrates” thus providing better interference [48]. Additionally, the 
siRNAs used in this study may need to be incubated with the cells for a longer period 
of time than 24 h. The half-life of KLB protein may be longer than anticipated so 
only incubating the cells with KLB siRNA for 24 h may not provide effective protein-
level knockdown. Accordingly, future work should include longer KLB siRNA 
treatments (48 or 72 h).      
5.7. Future Work 
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This study has conclusively shown high expression and association of FGFR4 and KLB in the 
LNCaP progression model of PCa compared to a BMSC model, HS27a. However, much work is 
required to investigate the role of FGFR4-KLB signaling in the setting of PCa. 
 
The association of FGFR4 and KLB as assayed with PLA is evident in C4-2B cells. It would be 
beneficial to conduct this assay in the other LNCaP cell lines to determine when along PCa 
progression FGFR4 and KLB are able to form a complex. Additionally, clinical samples of PCa 
should be examined for the association of FGFR4 and KLB.  As discussed above, FGFR4 and 
KLB protein expression reach a maximum of expression at different stages of progression and 
coordinately, they may only form co-receptor pairs at certain stages of disease progression.   
Although FGFR4-KLB did not induce ERK phosphorylation, this co-receptor pair may be 
involved in other mitogenic and cell-survival pathways. It would be beneficial to assay the state 
of the AKT cell survival pathway in the presence of FGF19.  
 
For a firm understanding of FGFR4-KLB signaling in PCa, siRNA knockdown experiments will 
be key. As discussed above, I was unable to obtain effective KLB siRNA knockdown. If 
effective knockdown is attained, assaying pS6 and FGFR4 expression should be done. If KLB is 
knocked down and pS6 levels are also reduced in the presence of FGF19, FGFR4-KLB may be 
playing a role in regulating the cell cycle. As was shown in Figure 4.3, FGF19 treatments did not 
induce further pS6 expression; however, in this state, the PCa cells may already be expressing 
maximal pS6 so treatment with FGF19 would have no effect and it would appear that FGFR4-
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KLB does not play a role in cell-cycle regulation. If however, FGFR4-KLB is involved in cell 
cycle regulation and KLB was effectively knocked down, we may see reduced pS6 expression 
that could not be rescued with FGF19 administration. This would place FGFR4-KLB as a 
regulator of the cell cycle.  
 
FGFR4-KLB may provide PCa cells with protection from chemotherapeutics. However, more 
data is required to determine in this chemotherapeutic protection is the case. In my experiment, 
cells were first pre-treated with FGFs for 24h, FGFs were removed, and CPT was incubated with 
the cells for an additional 24h. After CPT treatment, multiple washes were done to remove the 
CPT and in the process, many cells were lost as is common with C4-2B cells. Additional care 
during these washes is required to prevent cellular loss to obtain adequate sample sizes for 
analysis. It may also be beneficial to obtain quantitative data of live/dead cells for a more 
complete study.  
 
5.8. Summary and Significance of Findings 
In summary, I determined that FGFR4 and KLB mRNA and protein are highly expressed in the 
LNCaP progression model of PCa when compared to the HS27a cell line model of BMSCs. I 
was also able to use PLA to show that FGFR4 and KLB are within 40 nm of each other forming 
a co-receptor pair. Surprisingly, FGFR4-KLB did not regulate ERK phosphorylation or pS6 
expression. However, ACC2 expression was greatly reduced in C4-2B cells and FGFR4-KLB 
may provide chemotherapeutic resistance to PCa cells. As discussed above, FGFR4 has been 
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associated with PCa aggressiveness while KLB has only been associated with metabolic 
signaling associated with the liver. This study has shown expression of both receptors as well as 
a high degree of colocalization on PCa.  The combinatorial expression of both receptors and 
formation of a functional co-receptor pair may allow PCa cells to utilize previously unknown 
signaling pathways enhancing PCa survival and success in the bone. FGFR4-KLB expression 
and signaling pathways may provide excellent targets for future therapies.  
 
5.9. Final Thoughts    
Although FGFR4-KLB have yet to be demonstrated to be regulators of cellular signaling, 
the presence of these proteins at high levels in PCa models make them attractive targets for 
future therapies. Recently, the Farach-Carson laboratories in conjunction with Dr. Daniel 
Wagner, Dr. Dmitri Lapotko and Dr. Kate Hleb (Rice University) have begun to investigate the 
effectiveness of plasmonic nanobubble-mediated therapies. In early work to develop an in vivo 
model for PNB-mediated PCa cell detection and ablation, the Wagner lab xenografted C4-2B 
cells into zebrafish embryos and observed C4-2B cell localization in ventral tail fin of these 
embryos [34]. With a reliable PCa xenograft model in place, targeting multiple highly expressed 
cell surface receptors with antibody-mediated gold nanoparticles is highly desirable because 
tumors and populations of cancer cells residing in the tumor are quite heterogeneous. In their 
previous work, it was shown that combined. Prostate Specific Membrane Antigen (PSMA) and 
Epidermal Growth Factor Receptor (EGFR) targeted nanoparticles for plasmonic nanobubble 
PCa cell ablation in vitro has been quite effective [18, 20, 34, 48]. FGFR4-KLB may be an even 
better target to increase selectivity and effectiveness of this technology as these proteins form 
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coreceptor pairs, unlike PSMA and EGFR. Having a coreceptor pair may more easily facilitate 
nanoparticle cluster formation and nanobubble generation due to two reasons: first, the  close 
proximity of the two receptors allow nanoparticles bound to each receptor may be up taken into 
the cell in the same endocytic vesicle, as opposed to different vesicles that result from distant 
receptors. Receptors in close proximity would more readily form vesicles with many 
nanoparticles, making nanobubble formation easier and more specific to cancer cells. Second, by 
selecting two receptors specifically expressed at high levels in cancerous tissue would allow for 
greater therapeutic specificity, thus reducing damage to surrounding non-cancerous tissues.    
By furthering our understanding of FGFR4-KLB signaling and targeting FGFR4-KLB for 
therapeutics, new avenues of novel cancer treatments may come to light.   
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